Valeur202020212022202320242025Total du passif6.73 M6.73 M6.73 M6.73 M6.73 M11.38 MTotal des capitaux propres—————-3.8 MTotal du passif et des capitaux propres6.73 M6.73 M6.73 M6.73 M6.73 M7.58 MDette totale——————Dette nette——————
Oncolytics Biotech Inc. - Common Stock
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.